Drug maker Novartis doesn’t have a cure for the world’s economic problems, but its stock can pep up investors’ portfolios. The Swiss company (NOVN.Switzerland) this week reported earnings for 2012 that largely met expectations. However, it is Novartis’ forecast of good times ahead that is the cause for excitement. Novartis said its next growth phase [...]